Heraldo Possolo de Souza

Heraldo Possolo de Souza

Auto-generated profile, based on publicly available information

Heraldo Possolo de Souza

Universidade de São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JAJulio Cesar Garcia de Alencar
Julio Cesar Garcia de Alencar
CMClaudia de Lucena Moreira
Claudia de Lucena Moreira
AMAlicia Dudy Müller
Alicia Dudy Müller
CCCleuber Esteves Chaves
Cleuber Esteves Chaves
MFMarina Akemi Fukuhara
Marina Akemi Fukuhara
HSHeraldo Possolo Souza
Heraldo Possolo Souza
Background: A local increase in angiotensin 2 after inactivation of angiotensin-converting enzyme 2 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce a redox imbalance in alveolar epithelium cells, causing apoptosis, increased inflammation and, consequently, impaired gas exchange. We hypothesized that N-acetylcysteine (NAC) administration could restore this redox homeostasis and suppress unfavorable evolution in patients with coronavirus disease 2019 (COVID-19). Methods: This was a double-blind, randomized, placebo-controlled, single-center trial conducted at the Emergency Department of Hospital das Clínicas, São Paulo, Brazil, to determine whether NAC in high doses can avoid respiratory failure in patients with COVID-19. We enrolled 135 patients with severe COVID-19 (confirmed or suspected), with an oxyhemoglobin saturation 24 breaths/minute. Patients were randomized to receive NAC 21 g (~300 mg/kg) for 20 hours or dextrose 5%. The primary endpoint was the need for mechanical ventilation. Secondary endpoints were time of mechanical ventilation, admission to the intensive care unit (ICU), time in ICU, and mortality. Results: Baseline characteristics were similar between the 2 groups, with no significant differences in age, sex, comorbidities, medicines taken, and disease severity. Also, groups were similar in laboratory tests and chest computed tomography scan findings. Sixteen patients (23.9%) in the placebo group received endotracheal intubation and mechanical ventilation, compared with 14 patients (20.6%) in the NAC group (P = .675). No difference was observed in secondary endpoints. Conclusions: Administration of NAC in high doses did not affect the evolution of severe COVID-19. Clinical Trials Registration: Brazilian Registry of Clinical Trials (REBEC): U1111-1250-356 (http://www.ensaiosclinicos.gov.br/rg/RBR-8969zg/).

1 January 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
NNNaomi Kondo Nakagawa
Naomi Kondo Nakagawa
KOKatia Moreno Garcia Oliveira
Katia Moreno Garcia Oliveira
ALAndrew Lockey
Andrew Lockey
FSFederico Semeraro
Federico Semeraro
PAPriscila Aikawa
Priscila Aikawa
Bernd BöttigerBernd Böttiger
Bernd Böttiger

28 May 2022 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Open access
PDF file
RDRodolfo Damiano
Rodolfo Damiano
DNDeusdedit Brandão Neto
Deusdedit Brandão Neto
JOJoão Vitor Ribeiro Oliveira
João Vitor Ribeiro Oliveira
JSJonatas Magalhães Santos
Jonatas Magalhães Santos
JAJulia Vallin Rodrigues Alves
Julia Vallin Rodrigues Alves
SCSilvia Figueiredo Costa
Silvia Figueiredo Costa
Preliminary methodologically limited studies suggested that taste and smell known as chemosensory impairments and neuropsychiatric symptoms are associated in post-COVID-19. The objective of this study is to evaluate whether chemosensory dysfunction and neuropsychiatric impairments in a well-characterized post-COVID-19 sample. This is a cohort study assessing adult patients hospitalized due to moderate or severe forms of COVID-19 between March and August 2020. Baseline information includes several clinical and hospitalization data. Further evaluations were made using several different reliable instruments designed to assess taste and smell functions, parosmia, and neuropsychiatric disorders (using standardized psychiatric and cognitive measures). Out of 1800 eligible individuals, 701 volunteers were assessed on this study. After multivariate analysis, patients reporting parosmia had a worse perception of memory performance (p < 0.001). Moderate/severe hypogeusia was significantly associated with a worse performance on the word list memory task (p = 0.012); Concomitant moderate/severe olfactory and gustatory loss during the acute phase of COVID-19 was also significantly associated with episodic memory impairment (p = 0.006). We found a positive association between reported chemosensory (taste and olfaction) abnormalities and cognition dysfunction in post-COVID-19 patients. These findings may help us identify potential mechanisms linking these two neurobiological functions, and also support the speculation on a possible route through which SARS-CoV-2 may reach the central nervous system.


23 November 2018 in Metabolites
Verified
Journal Article
Open access
PDF file
JFJarlei Fiamoncini
Jarlei Fiamoncini
CBCarina Fernandes Barbosa
Carina Fernandes Barbosa
JJJosé Rubens Arnoni Junior
José Rubens Arnoni Junior
JJJosé Celestino Araújo Junior
José Celestino Araújo Junior
CTCinthia Taglieri
Cinthia Taglieri
TLThais Lima
Thais Lima
Roux-en-Y gastric bypass (RYGB) is an effective method to achieve sustained weight loss, but the mechanisms responsible for RYGB effects have not yet been fully characterized. In this study, we profiled the concentrations of 143 lipid metabolites in dry blood spots (DBS) of RYGB patients. DBS from obese patients (BMI range 35–44 kg/m2) were collected 7 days before, 15 and 90 days after the surgery. LC-MS/MS was used to quantify acylcarnitines, phosphatidylcholines, sphingomyelins and bile acids. RYGB caused a rapid increase in acylcarnitine levels that proved to be only transient, contrasting with the sustained decrease in phosphatidylcholines and increase of sphingomyelins and bile acids. A PLS-DA analysis revealed a 3-component model (R2 = 0.9, Q2 = 0.74) with key metabolites responsible for the overall metabolite differences. These included the BCAA-derived acylcarnitines and sphingomyelins with 16 and 18 carbons. We found important correlations between the levels of BCAA-derived acylcarnitines and specific sphingomyelins with plasma cholesterol and triacylglycerol concentrations. Along with the marked weight loss and clinical improvements, RYGB induced specific alterations in plasma acylcarnitines, bile acid and phospholipid levels. This calls for more studies on RYGB effects aiming to elucidate the metabolic adaptations that follow this procedure.

1 January 2014 in Revista Brasileira de Terapia Intensiva
Verified
Journal Article
Open access
MHMike Yoshio Hamasaki
Mike Yoshio Hamasaki
HBHermes Vieira Barbeiro
Hermes Vieira Barbeiro
HSHeraldo Possolo de Souza
Heraldo Possolo de Souza
MMMarcel c c Machado
Marcel c c Machado
FSFabiano Pinheiro da Silva
Fabiano Pinheiro da Silva
To evaluate and understand the clinical implications of the plasma levels of a soluble isoform of a receptor for advanced glycation end products (sRAGE) in different stages of sepsis. Serum sRAGE values in patients who were divided into intensive care unit control, severe sepsis, septic shock and recovery from septic shock groups were statistically analyzed to assess quantity (Kruskal-Wallis), variability (Levine test) and correlation (Spearman rank test) with certain inflammatory mediators (IL-1 α, IL-6, IL-8, IL-10, IP-10, G-CSF, MCP-1, IFN-γ and TNF-α). No changes in sRAGE levels were observed among the groups; however, the septic shock group showed differences in the variability of sRAGE compared to the other groups. A positive correlation with all the inflammatory mediators was reported in the septic shock group. sRAGE levels are associated with worse outcomes in patients with septic shock. However, a statistical correlation analysis with other proinflammatory cytokines indicated that the pathways leading to those outcomes are different depending on the sRAGE levels. Future studies to elucidate the pathophysiological mechanisms involving sRAGE in models of sepsis are of great clinical importance for the safe handling of this biomarker.